P. Pancheri, R. Romiti - Vol. 6, Settembre 2000, num.3
Testo Immagini Bibliografia Summary Riassunto Indice
Terapia dell'Ansia Generalizzata con farmaci antidepressivi.
Il ruolo della venlafaxina a Rilascio Prolungato
Treatment of generalised anxiety with antidepressant drugs. The role
of venlafaxine-XR
1 Berrios G.
Anxiety disorders: a conceptual history.
J Affect Disord 1999;56:83-94.
2 American Psychiatry Association.
Diagnostic and Statistical Manual of Mental Disorders. Second Edition
DSM-II.
American Psychiatry Association Washington D.C. 1968.
3 American Psychiatry Association.
Diagnostic and Statistical Manual of Mental Disorders. Third Edition DSM-III.
American Psychiatry Association Washington D.C. 1980.
4 American Psychiatry Association.
Diagnostic and Statistical Manual of Mental Disorders. Third Edition Revised
DSM-III-R.
American Psychiatry Association Washington D.C. 1987.
5 American Psychiatry Association.
Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition
DSM-IV.
American Psychiatry Association Washington D.C. 1994.
6 Wittchen HU, Zhao S, Kessler RC, Eaton WW.
DSM-III-R Generalized Anxiety Disorder in the national comorbidity survey.
Arch Gen Psychiatry 1994;51:355-64.
7 Judd LL, Kessler RC, Paulus MP, Zeller PV, Wittchen HU, Kunovac JL.
Comorbidity as a fundamental feature of generalized anxiety disorders:
results from the National Comorbidity Study (NCS).
Acta Psychiatrica Scand 1998;98(Suppl. 393):6-11.
8 Yonkers KA, Dyck IR, Warshaw M, Keller MB.
Factors predicting the clinical course of generalized anxiety disorder.
Br J Psychiatry 2000;176:S44-S49.
9 Rogers MP, Warshaw M, Goisman RM, Goldenberg I, Rodriguez-Villa F, Mallya
G, et al.
Comparing primary and secondary generalized anxiety disorder in a long-term
naturalistic study of anxiety disorders.
Depress Anxiety 1999;10:1-7.
10 Massion AO, Warshaw MG, Keller MB.
Quality of life and psychiatric morbidity in panic disorder and generalized
anxiety disorder.
Am J Psychiatry 1993;150:600-7.
11 Goldberg DP, Rickels K, Dowing R, Hesbacher P.
A comparison of two psychiatric screening tests.
Br Journal Psychiatry 1976;129:61-7.
12 Huppert FA, Walters DE, Day NE Elliott BJ.
The factor structure of the General Health Questionnaire (GHQ-30). A reliability
study of 6317 community residents.
Br J Psychiatry 1989;155;178-85.
13 Roth M, Mountojoy C.
Classification and diagnosis of anxiety and depressive disoreders and
some implications for clinical practice and enquiry.
Hum Psychopharmacol 1999;14:S40-S71.
14 Brugnoli R, Pacitti F, Iannitelli A, Pancheri P.
G Ital Psicopatol 2000;4 (in stampa).
15 Pasquini M, Biondi M, Picardi A, Gaetano P, Pancheri P.
MMPI-2 e dimensioni psicopatologiche dei disturbi depressivi: uno studio
di analisi fattoriale in una popolazione ambulatoriale.
Riv Psichiatria 1999;34:200-7.
16 Khan RJ, McNair DM, Lipman RS.
Imipramine and chlordiazepoxide in depressive and anxiety disorders.
II Efficacy in anxious outpatients.
Arch Gen Psychiatry 1986;43:79-85.
17 Hoehn-Saric R, McLeod DR, Zimmerli WD.
Differential effects of alprazolam and imipramine in generalized anxiety
disorder: somatic versus psychic symptoms.
J Clin Psychiatry 1988;49:293-301.
18 Rickels K, DowningR, Schweizer E, Hassman H.
Antidepressant for the treatment of generalized anxiety disorder. A placebo-controlled
comparison of imipramine, trazodone and diazepam.
Arch Gen Psychiatry 1993;50:884-95.
19 McLeod DR, Hoehn-Saric R, Zimmerli WD, De Souza EB, Oliver LK.
Treatment effects of alprazolam and imipramine: physiological versus subjective
changes in patients with generalized anxiety disorder.
Biol Psychiatry 1990;28:849-61.
20 Conti L, Pinder RM.
A controlled comparative trial of mianserin and diazepam in the treatment
of anxiety states in psychiatric out-patients.
J Int Med Res 1979;7:285-9.
21 Bjaertnaes A, Block JM, Hafstad PE.
A multicentre placebo-controlled trial comperig the efficacy of mianserin
and chlordiazepoxide in general clinical practice with primary anxiety.
Acta Psychiatr Scand 1982;66:199-207.
22 Den Boer JA, Westnberg HG, Kamerbeek WD, Verheven WM, Kahn RS.
Effects of serotonin uptake inhibitors in anxiety disorders: a double-blind
comparison of clomipramine and fluvoxamine.
Int Clin Psychopharmacol 1987;2:21-32.
23 Carrasco JL, Diaz-Marsa M, Saiz-Ruiz J.
Sertraline in the treatment of mixed anxiety and depression disorder.
J Affect Disord 2000;59:67-69.
24 Birmaher B, Watrman GS, Ryan N.
Fluoxetine for childhood anxiety disorders.
J Am Acad Child Adolesc Psychiatry 1994;33:993-9.
25 Delini-Stula A, Cameron A, Angst J.
Comparative efficacy of antidepressants on anxiety features in depression:
a meta-analysis of double-blind studies of imipremine and moclobemide against
placebo.
International Journal of Psychiatry in Clinical Practice 2000;4:111-7.
26 Feighner JP, Cohn JB.
Analysis of individual symptoms in generalized anxiety - A pooled, multistudy,
double-blind evaluation of buspirone.
Neuropsychobiology 1989;21:124-30.
27 Gammans RE, Stringfellow JC, Hvizdos AJ.
Use of buspirone in patients with generalized anxiety disorder coexisting
depressive symptoms. A meta-analysis of eigth randomized controlled studies.
Neuropsychobiology 1992;25:193-201.
28 Ross CA, Matas M.
A clinical trial of buspirone and diazepam in the treatment of generalised
anxiety disorder.
Can J Psychiatry 1987;32:351-5.
29 Feighner JP, Merideth CH, Hendrickson GA.
A double-blind comparison of buspirone and diazepam in outpatients with
generalized anxiety disorder.
J Clin Psychiatry 1982;43:103-8.
30 Ansseau M, Papart P, Gérard MA, von Frenckell R, Franck G.
Controlled comparison of buspirone and oxazepam in generalized anxiety.
Neuropsychobiology 1990;24:74-8.
31 Strand M, Hetta J, Rosen A.
A double-blind, controlled trial in primary care patients with generalised
anxiety: a comparison between buspirone and oxazepam.
J Clin Psychiatry 1990;51(suppl 9):40-5.
32 Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB.
Treatment of generalized anxiety disorder: preliminary clinical experience
with buspirone.
J Clin Psychiatry 1990;51(suppl 9):31-9.
33 Enkelmann R.
Alprazolam versus buspirone in the treatment of outpatients with generalized
anxiety disorder.
Psychopharmacology (Berl) 1991;105:428-32.
34 Bohm C, Placchi M, Stallone F.
A double-blind comparison of buspirone, clobazam, and placebo in patients
with anxiety treated in general practice setting.
J Clin Psychopharmacol 1990;10(suppl 3):38-42.
35 Feigner JP.
Buspirone in the long-term treatment of generalized anxiety disorder.
J Clin Psychiatry 1987;48(suppl 12):3-6.
36 Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini
M.
Assessment of the efficacy of buspirone in patients affected by generalized
anxiety disorder, shifting to buspirone from prior treatment with lorazepam:
a placebo-controlled, double-blind study.
J Clin Psychopharmacol 1995;15:12-9.
37 Pancheri P.
La specificità terapeutica delle molecole antidepressive.
In: Pancheri P, Cassano GB, eds. Specificità e aspecificità
terapeutica dei farmaci antidepressivi. Firenze: Scientific Press 1995.
38 Heninger GR, Charney DS.
Mechanism of action of antidepressant treatments. Implications for the
etiology and treatment of depressive disorders.
In: Meltzer HY, ed. Psychopharmacology: The third Generation in Progress.
New York: Raven Press 1987:535-44.
39 Troy SM, Dilea C, Martin QT, Leister CA, Fruncillo RJ, Juskd WV, Chiang
ST.
Pharmacokinetics of once-daily venlafaxine extended release in healthy
volunteers.
Curr Therap Res 1997;58:504-14.
40 Thase ME.
Efficacy and tolerability of once-daily Venlafaxine extended release (XR)
in outpatients with major depression.
J Clin Psychiatry 1997;58:393-8.
41 Cunningham LA.
Once-daily Venlafaxine extended release (XR) and Venlafaxine immediate
release (IR) in outpatients with major depression.
Ann Clin Psychiatry 1997;9:157-64.
42 Rudolph RL.
Efficacy and and tolerability of once-daily Venlafaxine XR vs fluoxetina
and placebo in depressed outpatients.
Eur Neuropsychopharmacol 1997;(suppl 2):S168.
43 Salinas E.
Once-daily venlafaxine XR versus paroxetine in outpatients with major
depression.
Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, July,
1998.
44 Rudolph RL, Entsuah R, Chitra R.
A meta-analysis of the effects of venlafaxine on anxiety associated with
depression.
J Clin Psychopharmacol 1998;18:136-44.
45 Khan A, Upton V, Rudolph RL, Entsuah R, Leventer SM.
The use of venlafaxine in the treatment of major depression associated
with anxiety: a dose-response study.
J Clin Psychopharmacol 1998;18:19-25.
46 Feighner JP, Entsuah R, McPherson MK.
Efficacy of once-daily venlafaxine extended release (XR) for symptoms
of anxiety in depressed outpatients.
J Affect Disord 1998;47:55-62.
47 Iskandar H, Silverstone P.
Efficacy and tolerability of once-daily venlafaxine XR vs fluoxetine in
depressed outpatients with concomitant anxiety.
Eur Neuropsychopharmacol 1997;(suppl 2):S67-S308.
48 Silverstone P, Ravindran A.
Once-daily Venlafaxine extended release (XR) compared with fluoxetine
in outpatients with depression and anxiety.
J Clin Psychiatry 1999;60:22-8.
49 Haskins JT, Aguilar L, Pallay A, Rudolph R.
Double-blind, placebo-controlled study of once daily venlafaxine XR in
outpatients with generalized anxiety disorder.
Eur Neuropsychopharmacol 1998;(suppl 2):S257.
50 Davidson JRT, DuPont RL, Hedges D, Haskins JT.
Efficacy, safety and tolerability of venlafaxine extended release and buspirone
in outpatients with generalized anxiety disorder.
J Clin Psychiatry 1999;60:528-35.
51 Haskins JT, Rudolph R Aguilar L, Entsuah R, Salinas E.
Venlafaxine XR (V-VR) is an efficacious short- and long-term treatment
for generalized anxiety disorder (GAD).
Eur Neuropsychopharmacol 1998;(suppl 2):S265.
52 Hackett D, Parks V, Salinas E.
A 6 month evaluation of 3 dose levels of venlafaxine extended-release in
non-depressed outpatients with generalised anxiety disorder.
Anxiety Disorders Association of America 19° Annual Conference, 25-28 Marzo
1999; San Diego, California.
53 Boulenger JP, Boyer P.
Mixed anxiety and depression: clinical issues.
Eur J Psychiatry 1994;9 (suppl. 2):219-26.
54 Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ.
Major depression and generalised anxiety disorder. Same genes, (partly)
different environments?
Arch Gen Psychiatry 1992;49:716-22.
55 Rapaport MH, Paniccia G, Judd LL.
A review of social phobia.
Psychopharmacol Bull 1995;31:125-9.
56 Uhde TW, Boulenger JP, Vittone BJ, Post RM.
Historical and modern concepts of anxiety: a focus on adrenergic function.
In: Ballanger JC, ed. Biology of agoraphobia. Washington D.C.:
American Psychiatric Press 1984.
57 Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR.
Noradrenergic dysregulation in panic disorder.
In: Ballanger JC, ed. Neurobiology of panic disorder. New York:
Wiley-Liss, 1990.
58 Norman TR, Judd FK, Burrows GD.
Catecholamines and anxiety.
In: Burrows GD, Roth Sir, Noyes R Jr, eds. The neurobiology of anxiety.
Handbook of anxiety. vol 3. Amsterdam: Elsevier 1990.
59 Redmond DE Jr.
Studies of the nucleus locus coeruleus in monkeys and hypotheses for neuropsychopharmacology.
In: Meltzer HY, ed. Psychopharmacology: the third generation in progress.
New York: Raven Press 1987.
60 Louie AK, Lewis TB, Lannon RA.
Use of low-dose of fluoxetine in major depression and panic disorder.
J Clin Psychiatry 1993;54:435-8.
61 Tiffon L, Coplan JD, Papp La, Gorman Jm.
Augmentation strategies with tricyclic or fluoxetine treatment in seven
partially responsive panic disorder patients.
J Clin Psychiatry 1994;55:66-9.
62 Pecknold JC.
Serotonin abnormalities in panic disorder.
In: Ballenger JC, ed. Neurobiology of panic disorder. New York:
Wiley-Liss 1990.
63 Cross-National Collaborative Panic Study, Second Phase Investogators.
Drug treatment of panic disorder. Comparative efficacy of alprazolam,
imipramine, and placebo.
Br J Psychiatry 1992;160:191-205.
64 Deakin JFW.
Three distinct roles of 5-HT in anxiety, panic and depression.
In: Montgomery SA, Corn TH, eds. Psychopharmacology of depression.
Oxford: Oxford University Press 1994; 87-101.
65 Zhu MY, Klimek V, Dilley GE, Haycock JW, Stockmeier C, Overholser JC,
et al.
Elevated levels of tyrosine hidroxylase in the locus coeruleus in major
depression.
Biol Psychiatry 1999;46:1275-86.
66 Anand A, Charney DS.
Norepinephrine dysfunction in depression.
J Clin Psychiatry 2000;61(suppl.10):16-24.
67 Ressler KJ. Nemeroff CB.
Role of norepinephrine in the pathophisiology and treatment of mood disorders.
Biol Psychiatry 1999;46:1219-33.
68 Nelson JC.
A review of the efficacy of serotoninergic and noradrenergic reuptake
inhibitors for treatment of major depression.
Biol Psychiatry 1999;46:1301-8.
69 Montgomery SA.
Is there a role for a pure noradrenergic drug in the treatment of depression?
Eur Neuropsychopharmacol 1997;7(suppl 1):S3-S9.
70 Dubini A, Bosc M, Polin V.
Do noradrenaline and serotonin differentially affect social motivation
and behaviour?
Eur Neuropsychopharmacol 1997;7(suppl 1):S49-S55.
71 Sullivan GM, Coplan JD, Kent JM, Gorman JM.
The noradrenergic system in pathological anxiety: a focus on panic with
relevance to generalised anxiety and phobias.
Biol Psychiatry 1999;46:1205-18.